Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S.

Economists saw “limited” risk to the pharmaceutical firm’s stock, despite some expected impact on Tylenol consumption.

President Donald Trump is set to speak today on how Tylenol may be linked to autism. Here's when, who makes Tylenol, and ...

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

Shares may be rising because investors expected the White House to announce stricter regulations on the medication, Citi ...

Earlier this week, the Trump administration publicly warned of a possible link between prenatal Tylenol use and autism, ...

Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a ...

Kenvue is the over-the-counter products company that was spun out of Johnson & Johnson in 2023. Tylenol, one of the most ...

Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump ...

Trump's warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a ...

Kenvue stock dropped following reports of a possible autism link to Tylenol's active ingredient, acetaminophen. Federal ...